袢利尿剂联合噻嗪类利尿剂治疗失代偿性心力衰竭:CLOROTIC试验
结果显示氢氯噻嗪组72小时体重下降更显著(2.3 vs 1.5 kg),但呼吸困难无显著改善,且肾功能损害更常见。
要点
- 氢氯噻嗪可增强急性心衰患者利尿反应,72小时体重下降更明显。
- 加用氢氯噻嗪未显著改善患者报告的呼吸困难。
- 氢氯噻嗪组肾功能损害发生率更高,需监测肾功能。
核心结论
- 在急性心衰患者中,袢利尿剂基础上加用氢氯噻嗪可改善利尿反应。
主要发现
- 氢氯噻嗪组72小时体重下降2.3 kg,安慰剂组1.5 kg,校正估计差异1.14(95%CI 1.84至0.42),P=0.002。
- 患者报告的呼吸困难视觉模拟量表曲线下面积两组无显著差异(960 vs 720,P=0.497)。
- 氢氯噻嗪组24小时尿量更多(1775 vs 1400 mL,P=0.05),每40 mg呋塞米对应的体重下降更显著(72和96小时,P=0.001)。
- 氢氯噻嗪组肾功能损害更常见(肌酐升高26.5 moL/L或eGFR下降50:46.5 vs 17.2,P=0.001),低钾血症两组相似。
- 30天和90天死亡率或再住院率两组无差异。
临床怎么用
- 对于急性心衰伴利尿反应不佳者,可考虑加用氢氯噻嗪以增强利尿,但需密切监测肾功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To evaluate whether the addition of hydrochlorothiazide (HCTZ) to intravenous furosemide is a safe and effective strategy for improving diuretic response in acute heart failure (AHF). METHODS AND RESULTS: A prospective, double-blind, placebo-controlled trial, including patients with AHF randomized to receive HCTZ or placebo in addition to an intravenous furosemide regimen. The coprimary endpoints were changes in body weight and patient-reported dyspnoea 72 h after randomization. Secondary outcomes included metrics of diuretic response and mortality/rehospitalizations at 30 and 90 days. Safety outcomes (changes in renal function and/or electrolytes) were also assessed. Two hundred and thirty patients (48 women, 83 years) were randomized. Patients assigned to HCTZ were more likely to lose weight at 72 h than those assigned to placebo [2.3 vs. 1.5 kg; adjusted estimated difference (notionally 95 confidence interval) 1.14 (1.84 to 0.42); P 0.002], but there were no significant differences in patient-reported dyspnoea (area under the curve for visual analogue scale: 960 vs. 720; P 0.497). These results were similar 96 h after randomization. Patients allocated to HCTZ showed greater 24 h diuresis (1775 vs. 1400 mL; P 0.05) and weight loss for each 40 mg of furosemide (at 72 and at 96 h) (P 0.001). Patients assigned to HCTZ more frequently presented impaired renal function (increase in creatinine 26.5 moL/L or decrease in eGFR 50; 46.5 vs. 17.2; P 0.001), but hypokalaemia and hypokalaemia were similar between groups. There were no differences in mortality or rehospitalizations. CONCLUSION: The addition of HCTZ to loop diuretic therapy improved diuretic response in patients with AHF.
引用
- Trullàs, Morales-Rull, Casado, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023. PMID: 36423214. doi:10.1093/eurheartj/ehac689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。